Consensus Denali Therapeutics Inc.

Stocks

DNLI

US24823R1059

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-08-31 EDT			5-day change	1st Jan Change
23.76 ^USD	-1.00%		-1.82%	+43.91%

08-25	B. Riley Adjusts Denali Therapeutics Price Target to $35 From $30, Maintains Buy Rating	MT
08-24	FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome	RE

Evolution of the Average Target: Denali Therapeutics Inc.

Evolution of the Target Price: Denali Therapeutics Inc.

Changes in Analyst Recommendations: Denali Therapeutics Inc.

c6d7d4318cd4b94e.b-AUIOwb2tn3ZkUauq26c7WjKaHg0kwKLAHoIj4yD8M.BohmaYVwquyALxRJ0O_KK9HpQcCu4HluS2acFgl-a4pduVN5gim4u6MTEA~46cc84f1814a03681fa0c9bd13332e74

Analysts' recommendations: Denali Therapeutics Inc.

08-25	B. Riley Adjusts Denali Therapeutics Price Target to $35 From $30, Maintains Buy Rating	MT
08-07	UBS Adjusts Price Target on Denali Therapeutics to $34 From $25, Maintains Buy Rating	MT
08-07	Wedbush Adjusts PT on Denali Therapeutics to $27 From $26, Maintains Outperform Rating	MT
07-16	Deutsche Bank Adjusts Price Target on Denali Therapeutics to $35 From $31, Maintains Buy Rating	MT
07-13	Wedbush Raises Price Target on Denali Therapeutics to $26 From $20, Keeps Outperform Rating	MT
05-26	Denali Therapeutics' Focus Shifts to Other Pipeline Assets After Phase 2b Study Failure, Morgan Stanley Says	MT
05-22	Morgan Stanley Cuts Price Target on Denali Therapeutics to $35 From $40, Keeps Overweight Rating	MT
05-22	Wedbush Cuts Price Target on Denali Therapeutics to $20 From $23, Keeps Outperform Rating	MT
05-22	Deutsche Bank Adjusts Denali Therapeutics Price Target to $31 From $35, Maintains Buy Rating	MT
05-14	Morgan Stanley Trims Price Target on Denali Therapeutics to $40 From $42, Keeps Overweight Rating	MT
05-11	Denali Therapeutics Seeing Encouraging Signals From Avlayah Launch, Oppenheimer Says	MT
05-08	Wedbush Adjusts Denali Therapeutics Price Target to $23 From $25, Maintains Outperform Rating	MT
04-21	Wedbush Cuts Price Target on Denali Therapeutics to $25 From $30, Keeps Outperform Rating	MT
03-26	Deutsche Bank Raises Price Target on Denali Therapeutics to $35 From $26, Keeps Buy Rating	MT
03-26	Morgan Stanley Lifts Price Target on Denali Therapeutics to $42 From $40, Keeps Overweight Rating	MT
01-07	UBS Adjusts Price Target on Denali Therapeutics to $25 From $24, Maintains Buy Rating	MT
12-11	Wedbush Trims Price Target on Denali Therapeutics to $30 From $31, Keeps Outperform Rating	MT
12-05	Wedbush Adjusts Denali Therapeutics Price Target to $31 From $30, Maintains Outperform Rating	MT
11-17	Centessa Pharmaceuticals, CG Oncology Drive Q3 Biotech Momentum, Morgan Stanley Says	MT
11-17	Morgan Stanley Raises Price Target on Denali Therapeutics to $32 From $30, Keeps Overweight Rating	MT
25-10-13	Denali's FDA Approval for Hunter Syndrome's Drug Candidate Extended	MT
25-10-13	Denali Therapeutics announces FDA review extension of BLA for Tividenofusp alfa	RE
25-10-13	Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)	CI
25-05-08	B. Riley Adjusts Denali Therapeutics Price Target to $30 From $35, Maintains Buy Rating	MT
25-05-08	Deutsche Bank Adjusts Denali Therapeutics Price Target to $28 From $29, Maintains Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	DENALI THERAPEUTICS INC.					+48.96%
	WUXI APPTEC CO., LTD.					+16.85%
	ARGENX SE					+9.86%
	WUXI BIOLOGICS (CAYMAN) INC.					+10.81%
	INSMED INCORPORATED					+68.87%
	BIONTECH SE					+17.86%
	PHARMAESSENTIA CORPORATION					-13.15%
	GENMAB A/S					+12.58%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+20.2%
	EXELIXIS, INC.					-2.66%
	Average					+19.02%
	Weighted average by Cap.					+16.78%